Author: Nicole Villeneuve
Press Releases
Swing Therapeutics Announces The Lancet Publication of Data from Phase 3 Trial of Stanza™ – a Digital Behavioral Therapy for Fibromyalgia Symptoms
Stanza demonstrated significant improvements compared to an active control on virtually all endpoints, including fibromyalgia-related well-being, pain intensity, pain interference,…
Read this Article
>
Research
Stanza Digital Behavioral Therapy Shown to Address Fibromyalgia Patient Unmet Needs
This month, Swing Therapeutics presented data from a real-world trial of Stanza, an FDA-cleared digital behavioral therapy for treatment of…
Read this Article
>
Research
Swing Announces Positive Early Results from Specialty Fibromyalgia Clinic
This week, Swing announced early outcomes from Swing Care, a specialty clinic dedicated to comprehensive, evidence-based fibromyalgia treatment. The results…
Read this Article
>
Press Releases
Swing Announces Positive Results from Pivotal Phase 3 Trial of Stanza, a Digital Therapy for Fibromyalgia Symptoms
SAN FRANCISCO–Swing Therapeutics, a leading developer of digital therapies for chronic pain conditions, today announced the successful completion of and…
Read this Article
>
Research
Swing Therapeutics Announces Long-Term Effectiveness Data from Studies of Stanza
Swing Therapeutics, a digital therapeutics company developing evidence-backed treatments for chronic pain conditions, announced the publication of new research data…
Read this Article
>
Press Releases
Swing Therapeutics Closes $10.3M Series A Funding Round
Swing Therapeutics, a digital therapeutics company developing evidence-backed treatments for autoimmune and chronic pain conditions, today announced that it has…
Read this Article
>
Press Releases
Swing Therapeutics Receives FDA Breakthrough Device Designation
Swing Therapeutics announced today that the FDA has granted Breakthrough Device Designation to the company’s digital therapeutic for the management…
Read this Article
>
Recent Comments